Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara announced that results from the Phase 3 IMPALA-2 trial of molgramostim in autoimmune pulmonary alveolar proteinosis will be presented at the ERS Congress 2026. Data from the 48-week open-label period showed continued improvements in lung function and exercise capacity, with biomarker reductions suggesting normalization of the underlying pathobiology.
Key figures
- Drug Name
- Molgramostim
- Phase Of Trial
- Phase 3
- Duration weeks
- 48
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.